Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

SRP6405

Sigma-Aldrich

ErbB2/HER2/CD340 human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)

Sign Into View Organizational & Contract Pricing

Synonym(s):
ERBB2, HER-2/neu, MLN19, NEU, NGL, TKR1
UNSPSC Code:
12352200
NACRES:
NA.32

biological source

human

recombinant

expressed in HEK 293 cells

tag

6-His tagged (C-terminus)

Assay

≥95% (SDS-PAGE)

form

lyophilized

potency

5-45 ng/mL

mol wt

calculated mol wt 72.4 kDa
observed mol wt 90-110 kDa (DTT-reduced. Protein migrates due to glycosylation.)

packaging

pkg of 10 and 50 μg

impurities

<1 EU/μg endotoxin (LAL test)

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... ErbB2(2064)

General description

Human epidermal growth factor receptor 2 (HER2), or erb-b2 receptor tyrosine kinase 2 (ErbB2) or tyrosine kinase receptor-1 (tkr-1), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the epidermal growth factor family of receptor tyrosine kinases (ErbBs). HER2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region and an intracellular tyrosine kinase domain. This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. HER2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.

Biochem/physiol Actions

Human epidermal growth factor receptor 2 (HER2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, overexpression of this protein causes breast cancer. Heterodimer complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of HER2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

Physical form

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

HER2: biology, detection, and clinical implications.
Gutierrez C and Rachel S
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)
The role of p95HER2 in trastuzumab resistance in breast cancer.
Eliyatkin N O, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English D P, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)
Esteban Cruz et al.
Cancers, 11(6) (2019-06-27)
Nanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor tissues due to tumor-selective accumulation through the enhanced permeability and retention effect (EPR). Gold nanoparticles (AuNP), in particular, possess highly appealing features for development as nanomedicines, such
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service